These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31983106)

  • 1. Paclitaxel-induced hepatic steatosis in patients with breast cancer.
    Inci F; Karatas F
    J BUON; 2019; 24(6):2355-2360. PubMed ID: 31983106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
    Kümmel S; Paepke S; Huober J; Schem C; Untch M; Blohmer JU; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Jackisch C; Schneeweiss A; Denkert C; Engels K; Klare P; Fasching PA; von Minckwitz G; Burchardi N; Loibl S
    Eur J Cancer; 2017 Oct; 84():1-8. PubMed ID: 28768217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.
    Villano JL; Mehta D; Radhakrishnan L
    Invest New Drugs; 2006 Sep; 24(5):455-6. PubMed ID: 16505953
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
    Klaassen U; Seeber S
    Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.
    Fukada I; Ito Y; Kobayashi K; Shibayama T; Takahashi S; Horii R; Akiyama F; Iwase T; Ohno S
    PLoS One; 2017; 12(9):e0184322. PubMed ID: 28898275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
    Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
    Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer].
    Hirono M; Kurebayashi J; Sonoo H; Nomura N; Okubo S; Udagawa K; Yamamoto Y; Ikeda M; Nakashima K; Tanaka K
    Gan To Kagaku Ryoho; 2004 May; 31(5):723-7. PubMed ID: 15170980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines.
    Fountzilas G; Athanassiades A; Giannakakis T; Bafaloukos D; Karakousis K; Dombros N; Kosmidis P; Skarlos D
    Eur J Cancer; 1996 Jan; 32A(1):47-51. PubMed ID: 8695240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer].
    Liu F; Jiang ZF; Song ST; Liu XQ; Wang T; Yan M; Zhang SH; Hao CF; Sun JZ; Shen G
    Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):56-8. PubMed ID: 15771802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for the development of paclitaxel-induced neuropathy in breast cancer patients.
    Robertson J; Raizer J; Hodges JS; Gradishar W; Allen JA
    J Peripher Nerv Syst; 2018 Jun; 23(2):129-133. PubMed ID: 29696771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment.
    Ellerbroek N; Martino S; Mautner B; Tao ML; Rose C; Botnick L
    Breast J; 2003; 9(2):74-8. PubMed ID: 12603378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal hepatic coma attributed to paclitaxel.
    Feenstra J; Vermeer RJ; Stricker BH
    J Natl Cancer Inst; 1997 Apr; 89(8):582-4. PubMed ID: 9106649
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer.
    Gelmon K; Eisenhauer E; Bryce C; Tolcher A; Mayer L; Tomlinson E; Zee B; Blackstein M; Tomiak E; Yau J; Batist G; Fisher B; Iglesias J
    J Clin Oncol; 1999 Oct; 17(10):3038-47. PubMed ID: 10506598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer.
    Kawakami T; Tsutsumi Y; Soma Y
    Arch Dermatol; 2009 Jan; 145(1):97-8. PubMed ID: 19153362
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-intensified weekly paclitaxel induces multiple nail disorders.
    Lüftner D; Flath B; Akrivakis C; Schweigert M; Prinz B; Mergenthaler HG; Petrides PE; Wernecke KD; Possinger K
    Ann Oncol; 1998 Oct; 9(10):1139-40. PubMed ID: 9834830
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
    Joerger M; Huitema AD; Huizing MT; Willemse PH; de Graeff A; Rosing H; Schellens JH; Beijnen JH; Vermorken JB
    Br J Clin Pharmacol; 2007 Nov; 64(5):622-33. PubMed ID: 17935602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.
    Ghoreishi Z; Keshavarz S; Asghari Jafarabadi M; Fathifar Z; Goodman KA; Esfahani A
    BMC Cancer; 2018 Oct; 18(1):958. PubMed ID: 30290775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01).
    Sato K; Inoue K; Saito T; Kai T; Mihara H; Okubo K; Koh J; Mochizuki H; Tabei T;
    Jpn J Clin Oncol; 2003 Aug; 33(8):371-6. PubMed ID: 14523055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.